Novavax Starts a Late-Stage Coronavirus Vaccine Clinical Trial

After running into some manufacturing issues, Novavax (NASDAQ:NVAX) is finally starting a phase 3 clinical trial for its coronavirus vaccine, NVX-CoV2373, in the U.S. and Mexico. The study, dubbed Prevent-19, will enroll 30,000 participants at 115 sites.